NAVB : Summary for Navidea Biopharmaceuticals, Inc - Yahoo Finance

U.S. Markets open in 8 hrs 21 mins

Navidea Biopharmaceuticals, Inc (NAVB)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.58+0.01 (+1.75%)
At close: 4:02PM EDT
People also watch
IMUCMSTXGALECLSNCPRX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.57
Open0.57
Bid0.00 x
Ask0.00 x
Day's Range0.56 - 0.58
52 Week Range0.26 - 1.51
Volume379,235
Avg. Volume1,041,614
Market Cap90.19M
Beta-0.92
PE Ratio (TTM)-6.99
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals13 days ago

    Why Navidea can recover no more than $12M if it wins against ex-lender in court

    The most Navidea Biopharmaceuticals Inc. could recover from the last of its legal battle with former lender CRG is $12 million – and the most it could lose is $7 million – after being forced to choose between pursuing a legal counterclaim or going out of business. Navidea's sale of North American rights to Lymphoseek, its first approved drug, to Cardinal Health Inc. for $83 million cash this month could not close until CRG released liens it placed on all of Navidea's assets. The lender, which had been pursuing a default claim and trying to seize Navidea's bank accounts since last April, released the liens only after Navidea agreed to a settlement requiring a promise not to pursue future claims against CRG.

  • American City Business Journals21 days ago

    Navidea closes Lymphoseek sale to Cardinal Health; lender CRG accepts loan payment, drops liens

    Navidea Biopharmaceuticals Inc. on Friday closed the sale of North American rights to its first approved drug to Cardinal Health Inc. for $83 million cash – 70 percent of which goes to fend off a lender trying for the past year to seize its bank accounts. The sale of the cancer diagnostic aid Lymphoseek could become worth $310 million over the life of the agreement , but most of the up-front payment is pledged elsewhere. From the proceeds, Navidea (NAVB) paid a $59 million temporary settlement with Houston-based lender CRG.

  • Business Wire23 days ago

    Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health

    Navidea Biopharmaceuticals announced today the completion of the sale to Cardinal Health of its Lymphoseek® product for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to lymph nodes for the staging of cancer in North America.